Print Page | Close Page

 
 

Sprout Pharmaceuticals, Inc.

Address: 4208 Six Forks Rd,, Suite 1010, Raleigh, North Carolina. NC 27609
 
Country: USA
 
Parent: Valeant Pharmaceuticals
 
Sectors: Proprietary Research & Manufacture
 
Telephone: +1 919.882.0850
 
Fax: +1 919.882.0855
 
Website: http://www.sproutpharma.com
 
- - -
 

Sectors

  • Proprietary Research & Manufacture
 
 
- - -
 

Categories

  • Clinical Development-Pipeline
 

A PHP Error was encountered

Severity: Notice

Message: Undefined property: stdClass::$company_licence_detail_in

Filename: profile/print_profile.php

Line Number: 302

Backtrace:

File: /home/pharmase/actex_application/views/front_end/profile/print_profile.php
Line: 302
Function: _error_handler

File: /home/pharmase/actex_application/controllers/Profile.php
Line: 483
Function: view

File: /home/pharmase/public_html/index.php
Line: 292
Function: require_once

A PHP Error was encountered

Severity: Notice

Message: Undefined property: stdClass::$company_licence_detail_out

Filename: profile/print_profile.php

Line Number: 303

Backtrace:

File: /home/pharmase/actex_application/views/front_end/profile/print_profile.php
Line: 303
Function: _error_handler

File: /home/pharmase/actex_application/controllers/Profile.php
Line: 483
Function: view

File: /home/pharmase/public_html/index.php
Line: 292
Function: require_once

A PHP Error was encountered

Severity: Notice

Message: Undefined property: stdClass::$company_licence_detail_distributor

Filename: profile/print_profile.php

Line Number: 304

Backtrace:

File: /home/pharmase/actex_application/views/front_end/profile/print_profile.php
Line: 304
Function: _error_handler

File: /home/pharmase/actex_application/controllers/Profile.php
Line: 483
Function: view

File: /home/pharmase/public_html/index.php
Line: 292
Function: require_once

A PHP Error was encountered

Severity: Notice

Message: Undefined property: stdClass::$company_licence_detail_researcher

Filename: profile/print_profile.php

Line Number: 305

Backtrace:

File: /home/pharmase/actex_application/views/front_end/profile/print_profile.php
Line: 305
Function: _error_handler

File: /home/pharmase/actex_application/controllers/Profile.php
Line: 483
Function: view

File: /home/pharmase/public_html/index.php
Line: 292
Function: require_once

A PHP Error was encountered

Severity: Notice

Message: Undefined property: stdClass::$company_licence_detail_description

Filename: profile/print_profile.php

Line Number: 306

Backtrace:

File: /home/pharmase/actex_application/views/front_end/profile/print_profile.php
Line: 306
Function: _error_handler

File: /home/pharmase/actex_application/controllers/Profile.php
Line: 483
Function: view

File: /home/pharmase/public_html/index.php
Line: 292
Function: require_once

 
- - -
 

News

 
29th March 2016
 

Sprout shareholders say company has set price too high, not marketing pill properly

 
Valeant/Sprout fails to satisfy investors in ‘female viagra’
 
-
 
 
10th December 2015
 

Sprout CEO Whitehead departs Valeant

 
In August, female libido drug maker Sprout agreed to a $1 billion buyout from Valeant ($VRX) that would make it a division of the Canadian pharma run by its current CEO, Cindy Whitehead. Now, though--less than four months later--Whitehead is on her way out.
 
-
 
 
20th August 2015
 

Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals

 
Laval, Quebec and Raleigh, NC — August 20, 2015 — Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and Sprout Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones.
 
-
 
 
18th August 2015
 

Sprout Pharmaceuticals Receives FDA Approval of ADDYI™ (Flibanserin 100 MG)

 
Raleigh, N.C. – August 18, 2015 – Sprout Pharmaceuticals, Inc. (Sprout) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of Addyi™ (flibanserin 100 mg) (pronounced add-ee), a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Addyi is the first and only FDA-approved treatment for this condition, the most common form of female sexual dysfunction, affecting up to 1 in 10 women in the United States.1
 
- - -
 
Printed: 10-Apr-2026 at 09:23:12 hrs
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com